0.00Open0.35Pre Close0 Volume7 Open Interest113.00Strike Price0.00Turnover7149.92%IV13.63%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.1035Delta0.0246Gamma285.00Leverage Ratio-1797.0169Theta0.0000Rho29.49Eff Leverage0.0002Vega
Merck & Co Stock Discussion
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...
No comment yet